Phase I dose-escalation study of the investigational Aurora A kinase (AAK) inhibitor MLN8237 as an enteric-coated tablet (ECT) formulation in patients with nonhematologic malignancies.
S. Sharma
Research Funding - Millennium
R. Kurzrock
No relevant relationships to disclose
L. Gouw
No relevant relationships to disclose
D. S. Hong
No relevant relationships to disclose
K. Jones
No relevant relationships to disclose
X. Zhou
Employment or Leadership Position - Millennium
H. Shi
Employment or Leadership Position - Millennium
H. Fingert
Employment or Leadership Position - Millennium
G. S. Falchook
Research Funding - Millennium